Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Net Income (2016 - 2025)

Historic Net Income for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Net Income rose 818.75% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10616.1%. This contributed to the annual value of -$14.0 million for FY2024, which is 8739.19% up from last year.
  • Heron Therapeutics' Net Income amounted to -$4.1 million in Q3 2025, which was up 818.75% from -$1.6 million recorded in Q2 2025.
  • Heron Therapeutics' Net Income's 5-year high stood at $4.2 million during Q4 2024, with a 5-year trough of -$62.9 million in Q1 2022.
  • Over the past 5 years, Heron Therapeutics' median Net Income value was -$24.9 million (recorded in 2023), while the average stood at -$27.2 million.
  • As far as peak fluctuations go, Heron Therapeutics' Net Income tumbled by 2074.11% in 2022, and later surged by 16573.57% in 2025.
  • Heron Therapeutics' Net Income (Quarter) stood at -$53.5 million in 2021, then surged by 61.98% to -$20.4 million in 2022, then surged by 49.79% to -$10.2 million in 2023, then skyrocketed by 140.83% to $4.2 million in 2024, then plummeted by 198.08% to -$4.1 million in 2025.
  • Its Net Income was -$4.1 million in Q3 2025, compared to -$1.6 million in Q2 2025 and $3.2 million in Q1 2025.